Skip to main content
OpenTrials
Completed

NCT Number: NCT03127384

Performance and Safety of Restylane Lidocaine for Treatment of Depressed Facial Acne Scars

The purpose of this study is to evaluate performance and safety of Restylane Lidocaine for treatment of depressed facial acne scars

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

25 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Darmstadt, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Intent to undergo treatment of depressed acne scars
  • Presence of 5-20 scars with a diameter of up to approximately 4 mm within the treatment area
  • Similar type, size and number of scars on both cheeks
  • Men or non-pregnant, non-breast feeding women
  • Fitzpatrick skin type I-IV
  • Signed and dated informed consent to participate in the study

Exclusion criteria

  • Presence of more than 3 scars per cheek (within the treatment area) of the following types: icepick scars or atrophic acne scars with a diameter of > 4 mm.
  • Active acne with inflammatory component
  • Use of per oral or topical (facial) substances containing retinoids, bensoyl peroxide, alpha-hydroxy acid at concentrations above 10%, beta-hydroxy acid at a concentration above 2%, or antibiotic treatment for active acne within 4 months before treatment
  • Use of isotretinoin within 6 months before treatment
  • Post-surgical scars in the treatment area
  • Previous tissue augmenting therapy or contouring with permanent filler or fat-injection in the treatment area
  • Previous tissue augmenting therapy, contouring or revitalisation treatment with Calcium Hydroxyapatite (CaHa), or Poly L-Lactic Acid (PLLA), in the treatment area within 24 months before treatment
  • Previous tissue augmenting therapy, contouring or revitalisation treatment with non-permanent filler such as hyaluronic acid (HA) or collagen in the treatment area within 12 months before treatment
  • Previous tissue revitalisation treatment with neurotoxin, laser or light, mesotherapy, chemical peeling or dermabrasion in the treatment area within 6 months before treatment
  • Previous surgery including aesthetic facial surgical therapy, liposuction, or tattoo in the treatment area
  • Any medical condition that, in the opinion of the treating Investigator, would make the subject unsuitable for inclusion (e.g. a chronic, relapsing or hereditary disease that may interfere with the outcome of the study)

Treatment and study plan

Restylane Lidocaine

Device

Hyaluronic acid based filler

No-treatment control

Other

No-treatment control

Primary outcomes

  1. Percentage of Participants With Lower Scar Severity in the Treated Cheek Compared to the Untreated Cheek

    Time frame: Month 3

    Overall scar severity assessed by blinded evaluator.

Secondary outcomes

  1. Percentage of Participants Improved on the Global Aesthetic Improvement Scale (GAIS)

    Time frame: Month 1, Month 3

    Assessed by blinded evaluator

Sponsors and collaborators

Lead sponsor

Galderma R&D

Industry

Registry information

Official study title

A Randomised, Evaluator-blind Comparative Study to Evaluate Performance and Safety of Restylane Lidocaine and No-treatment Control for Treatment of Depressed Facial Acne Scars

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Apr 25, 2017
Registry last updated
Aug 26, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.